Related Experiment Videos
[Research on TALF expression in Escherichia coli]
Dong-Ning Wang1, Xiang-Jun Sun, Wei-Jie Zhang
1College of Science and Technology, Shanghai Jiao Tong University, Shanghai 200030, China.
Summary
Tachyleus auti-lipoposaccharide (LPS) factor, or TALF, was expressed as a GST-TALF fusion protein. While the fusion protein showed no activity, thrombin digestion revealed strong bactericidal and LPS neutralizing properties, indicating therapeutic potential.
Area of Science:
- Biotechnology
- Molecular Biology
- Microbiology
Background:
- Gram-negative bacterial endotoxins pose significant health risks.
- Tachyleus auti-lipoposaccharide (LPS) factor (TALF) is a potential inhibitor of endotoxin.
- Developing effective methods for TALF production is crucial for its therapeutic application.
Purpose of the Study:
- To construct recombinant expression plasmids for TALF.
- To express and purify the TALF protein in E. coli.
- To evaluate the biological activity of the expressed TALF.
Main Methods:
- Gene cloning and recombinant plasmid construction (pGEX-4T-2, pET22b, pET28a).
- Bacterial transformation and expression in E. coli BL21 (DE3).
- Protein purification, thrombin digestion, and assessment of bactericidal and LPS neutralizing activities.
Main Results:
- TALF expression was unsuccessful in pET22b and pET28a vectors.
- A GST-TALF fusion protein was expressed in E. coli BL21, yielding 4mg at 91% purity per liter.
- The fusion protein exhibited no inherent activity, but thrombin-cleaved TALF demonstrated potent bactericidal and LPS neutralizing effects.
Conclusions:
- The GST-TALF fusion protein can be successfully produced in E. coli.
- Thrombin cleavage is essential to activate the bactericidal and LPS neutralizing activities of TALF.
- Activated TALF holds promise as a therapeutic agent against Gram-negative bacterial infections.